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CONTINUING EDUCATION II

A Pharmacist’s Role in the Prevention and Management of
Perioperative Atrial Fibrillation and Flutter

by Amanda Harmon, Pharm.D. Candidate Class of 2015; Bethany Smith, Pharm.D. Candidate Class of 2015;
Laura Tsu, Pharm.D., BCPS; Midwestern University College of Pharmacy – Glendale
Goal:
This home-study CPE has been developed to educate
pharmacists about recently published guidelines for
perioperative atrial fibrillation and flutter management
and prevention, and discuss the role a pharmacist can
have in the care of these patients.

At the conclusion of this lesson, successful participants
should be able to:

Objectives for Pharmacists:
1. Summarize the complications of post-operative atrial
fibrillation (POAF)
2. Define POAF in terms of electrocardiogram (EKG) findings
and clinical signs and symptoms
3. List rate control agents and their mechanism of action
and monitoring parameters
4. List rhythm control agents and their limitations
5. Identify potential candidates for rhythm control of POAF
6. Justify the preventative strategies recommended by the
POAF guidelines
7. Formulate an appropriate treatment plan for new-onset
POAF
8. Discuss management of anticoagulation for patients with
preexisting atrial fibrillation
Objectives for Technicians:
1. Understand some of the complications of post operative
Atrial Fibrillation
2. List rate control agents and what they are used for
3. List rhythm control agends and what they are used for
4. Learn preventative strategies recommended by POAF
guidelines

Introduction
Although thoracic surgeries save the lives of thousands of people every year, they are also associated
with an increased risk of cardiac arrhythmias, such as
atrial fibrillation (Afib). High risk procedures, such as
lung transplantations and esophagectomies have been
found to have greater than a 15% incidence of Afib
following surgery.1 Atrial fibrillation/flutter is the most
common sustained arrhythmia associated with thoracic
surgery.1 This adverse outcome is potentially preventable, and pharmacological therapy can play key role in
the care plan of these patients.
Afib is an irregular heart rhythm caused by chaotic
contracting of the atria of the heart. This lack of synCONTINUING EDUCATION

chronized beating can result in poor perfusion of
the body due to insufficient blood flow and increases the risk of emboli formation due to venous
stasis. Common clinical signs and symptoms of Afib
may include hypotension, dizziness, decreased
urinary output, and fatigue.1 On an electrocardiogram (EKG), Afib is characterized by no discernible
P waves and an irregularly irregular rhythm.
Postoperative/perioperative atrial fibrillation/
flutter (POAF) is Afib that occurs specifically during
the postoperative period and can be due to several factors. The risk factors for the development of
POAF are the same as those for the development
of Afib in nonsurgical patients.1 Oftentimes, the
stress of the surgery alone can be a risk factor for
experiencing an arrhythmia.1 The onset of POAF
most commonly occurs between two and four
days following surgery, and up to 98% of cases
resolve after six weeks.1 This adverse outcome is
a concern, however, because it can lead to hemodynamic instability, thrombus formation and even
heart failure due to sustained tachycardia. Risk of
POAF varies with the intensity of the cardiothoracic
surgery, higher risk coinciding with more invasive
and intense procedures. Other risk factors include
older age, hypertension, obesity, and smoking.1
See Table 1 for a more complete list of modifiable
and non-modifiable risk factors. The most serious
adverse event of POAF is formation of thromboemboli, which can lead to stroke and/or acute limb
ischemia.
Post-operative Afib is associated with an increased length of stay in the hospital, increased
morbidity and mortality, and increased healthcare
costs.1 Some studies have shown POAF to result
in increased length of stay by an average of three
days, and increased costs of care by up to 30%.2 It
is important for the pharmacist to be informed of
the current best practices in the management and
prevention of POAF to lead to better treatment
outcomes in this patient population.
Guidelines
Previously, management and prevention of
POAF has been directed by the Society of Thoracic
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Surgeons (STS) guidelines published in in the Journal
of Thoracic and Cardiovascular Surgery in 2011.3 In
September of 2014 the American Association for Thoracic Surgery (AATS) published guidelines for POAF,
titled “2014 AATS guidelines for the prevention and
management of perioperative atrial fibrillation and
flutter for thoracic surgical procedures” in the Journal
of Thoracic and Cardiovascular Surgery.1 These guidelines discuss new information and advances in POAF
therapy and provide updated recommendations on
the management of this condition.
The clinical guidelines start by providing definitions
for POAF as both an electro-physiologic and clinical
diagnosis. They recommend that the diagnosis of
POAF include clinically significant POAF that requires
treatment in addition to an EKG reading of Afib
lasting longer than 30 seconds.1 Patients at risk for arrhythmias or those who have substantial risk factors
for stroke should be continuously monitored via EKG
telemetry during the postoperative period to detect
any changes in rhythm.
The guidelines go on to recommend and review
various strategies for preventing POAF. Next, for
patients in whom new-onset POAF occurs, potential
treatment options are identified. The specifics of
these recommendations are discussed in the following sections and are the bulk of these clinical guidelines. Finally, recommendations for patients with preexisting Afib are provided, particularly with regards to
anticoagulation management.
Prevention of Postoperative Atrial Fibrillation
Postoperative Afib is a potentially serious complication of thoracic surgery and can be a preventable
incident. Recent evidence indicates that prevention
strategies previously reserved for high risk patients
may in fact be effective in all thoracic surgical patients. The strongest preventative recommendation
provided by the 2014 AATS guidelines is that all
patients taking β-blockers before surgery should continue them in the postoperative period (class I recommendation, indicating that the benefit outweighs
the risk).1 This recommendation is resultant of several
large meta-analyses and randomized studies, mostly
from cardiac surgery literature, that have shown withdrawal of β-blockers prior to surgery increases the
risk of developing POAF.1 It is thought that elevated
levels of norepinephrine in patients taking β-blockers
preoperatively with an interruption in therapy is assoCONTINUING EDUCATION

ciated with this higher risk.4 This recommendation is
in agreement with the 2011 ACCF/AHA Guideline for
Coronary Artery Bypass Graft (CABG) Surgery which
also suggest that beta-blockers be used both pre and
post-operatively.5 A second POAF prevention recommendation for all thoracic surgery patients, level class
IIb (benefit ≥ risk), is to replenish serum magnesium
stores when levels are depleted with intravenous
magnesium supplementation.1 Finally, the guidelines
classify the use of digoxin as a class III recommendation, advising against its use for preventing POAF.1
This is based off of current literature showing that
digoxin has been ineffective in preventing perioperative Afib.6 This is supported by the Guidelines
for CABG Surgery, which state that both digoxin and
nondihydropyridine calcium channel blockers (nonDHP CCBs) are not indicated for prophylaxis of POAF.5
It is important for the pharmacist to recognize these
pharmacological recommendations made by AATS so
that they can ensure the presence of evidence-based
therapy in preoperative patients to minimize risk.
For patients with an intermediate to high risk for
POAF additional strategies are offered. The guidelines
suggest that diltiazem can be considered as a prophylactic agent in patients who are not taking β-blockers
preoperatively, as a class IIa recommendation (benefit
outweighs the risk).1 Diltiazem generally does not
have the same blood pressure lowering effects that
β-blockers can have, and may be a good alternative
for patients in whom postoperative hypotension is
a concern. Its ability to decrease the risk of POAF is
thought to be related to its ability to decrease pulmonary vascular resistance.7 Other pharmacological
interventions discussed in the guidelines for these
higher risk patients include the use of intravenous
amiodarone postoperatively and initiation of atorvastatin in statin-naïve patients for the prevention
of POAF.1 The practice of using amiodarone postoperatively as prophylaxis is frequently seen in cardiovascular surgeries. This is largely due to the recommendations provided by the Guidelines for CABG
Surgery, which also suggest that amiodarone can be
used to decrease the risk of POAF.2 AATS specifically
recommends this practice for pulmonary resection
and esophagectomy procedures in this publication.
The recommendation for initiation of atorvastatin
is derived from the analysis of several studies investigating this indication. It is thought that statins
down-regulate the renin angiotensin system, and that
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it is through this mechanism that this class reduces risk
of Afib.8 Other novel prophylactic strategies continue
to be studied for additional options of POAF prevention
in these patients.
Management Strategies for New-onset POAF
For patients in whom POAF occurs, possible triggering causes should be carefully considered. Although
the irritation from the thoracic surgery itself is often
enough to explain new-onset POAF, other factors
should be considered so that they can be reduced or
removed if present. Examples of this include bleeding,
pulmonary embolism, airway compromise, and infection. In addition the guidelines recommend that catecholaminergic inotropic agents, such as dobutamine,
be reduced or stopped when hemodynamics allow.
Careful management of fluids and electrolytes is also
advised in patients with new-onset POAF, as an imbalance in these can be a trigger. These strategies are all
class I recommendations found in the 2014 guidelines,
again indicating that the benefit outweighs the risk.1
Once possible triggers of Afib are assessed and removed where possible, treatment of the arrhythmia
should be addressed. There are two approaches that
can be considered for the treatment of Afib: rate
control or rhythm control. The 2014 AATS guidelines
recommend that rate control therapy be used first-line
for stable patients with POAF.1 This recommendation
is based largely off of a landmark study named the
AFFRIM trial that was published in 2002 in the New
England Journal of Medicine. This study showed that
rate control was as effective as rhythm control for the
primary endpoints of death and incidence of ischemic
stroke, with fewer adverse drug events (ADEs) occurring in the rate control group.9 It is important to note,
however, that regardless of which treatment method is
used anticoagulation for patients who have been having episodes of Afib lasting longer than 48 hours should
be strongly considered. The guidelines recommend
using the CHA2DS2-VASc scoring system to determine
stroke risk in these patients. This scoring system is
shown in Figure 1. Pharmacists should be aware of the
different treatment options and their clinical pearls,
since many of the medications used in these approaches have several side effects and monitoring parameters. The following sections discuss the two treatment
approaches, emphasizing the medications that fall
under each category.
Rate Control Recommendations

The 2014 AATS POAF guidelines recommend
that rate control therapy be initiated as the firstline treatment option in hemodynamically stable
patients in whom POAF occurs. The following
agents are endorsed by the guidelines as being
effective for rate control. Rate control in POAF can
be achieved using intravenous (IV) or oral agents.
IV β-blockers and non-DHP CCBs, such as diltiazem
and verapamil, are commonly used since they can
often achieve rate control faster than other agents.
This section discusses the mechanisms of action of
the agents, as well as common side effects, dosing
recommendations, and contraindications/limitations. Important monitoring parameters for these
medications include EKG telemetry monitoring,
vital signs including blood pressure and heart rate,
electrolytes, and other labs such as serum creatinine (SCr) and complete blood count (CBC). A summary of these medications can be found in Table 2.
β-blockers:
β-blockers are Vaughan Williams class II agents.
Classification of the Vaughn Williams agents is
shown in Figure 2. These agents block the response
to β-adrenergic stimulation thereby decreasing
heart rate. Metoprolol is a commonly used β-blocker in Afib that is β-1 selective and as a result mainly
affects only cardiac tissue. IV dosing of metoprolol
tartrate (Lopressor) is 2.5-5.0 mg IV bolus over
2 min for a maximum of three doses.10 Esmolol
(Brevibloc) is a nonselective β-blocker with a quick
onset and shorter duration of action compared to
metoprolol. Esmolol is dosed intravenously at 0.5
mg/kg IV bolus over 1 min, then 0.05-0.3 mg/kg/
min IV continuous infusion.11 Both medications
reduce ventricular response in patients with Afib
within 5 minutes of administration. Significant
limitations and known side effects of β-blockers
include bradycardia, hypotension, bronchospasm
due to β-2 blocking activity, and avoidance of use
during heart failure exacerbation. Patients with
systolic heart failure and/or CAD have a compelling
indication for β-blocker therapy including the use of
carvedilol, metoprolol succinate, and bisoprolol as
these have favorable mortality data.
Non-DHP CCBs:
Diltiazem (Cardizem) is a non-DHP CCB and class IV
Vaughan Williams agent. IV diltiazem administered
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as a bolus and continuous infusion can control ventricular response in 70-90% of patients with recent-onset
Afib. The onset of action of diltiazem is 2-7 min. The
Atrial Fibrillation Follow-up Investigation of Rhythm
Management (AFFIRM) trial found oral diltiazem efficacious in controlling rest and exercise heart rate in approximately 60% of patients.9 Recommended IV dosing
of diltiazem is 0.25 mg/kg IV loading dose over 2 min,
then 5-15 mg/hour IV continuous infusion.12 A second
non-DHP CCB used for rate control is verapamil (Calan).
The recommended IV dosing for verapamil is 0.075 to
0.15 mg/kg (~ 5 to 10 mg for a 70-kg patient) administered as a bolus over 2 minutes; may give an additional
10 mg after 30 minutes if no response, then 0.005 mg/
kg/minute as a continuous infusion.13 Common side
effects of the non-DHP CCBs include hypotension,
bradycardia, and constipation. Limitations of non-DHP
CCBs include use during heart failure exacerbations as
this class of medication can worsen heart failure.
Digoxin (Lanoxin):
Digoxin’s mechanism of action is inhibition of sodium potassium ATPase. This enzyme, commonly known
as the sodium-potassium pump, is responsible for
transporting sodium ions out and potassium ions into
cells. Inhibition of this pump causes increased intracellular sodium concentrations which leads to increased
intracellular calcium concentrations. Digoxin increases
the force and velocity of myocardial systolic contraction
but also slows heart rate. Digoxin has positive inotropic
and negative chronotropic effects. This is significant
since it does not cause hypotension which is a limitation to many of the other Afib medications. The loading
dose for IV digoxin is 0.5 to 0.75 mg bolus followed by
0.25 mg IV every 2-6 hours to a maximum dose of 1.5
mg over 24 hours. This dosing has an onset of action
of 30 minutes to 2 hours.14 The maintenance dose is
based on lean body weight, renal function, age, and
concomitant medications. Digoxin is effective for rate
control at rest but requires concomitant use with either
a β-blocker or non-DHP CCB to achieve exercise rate
control. Therefore, digoxin should only be used as combination therapy rather than monotherapy. Also, digoxin should not be used for prophylaxis against Afib. It is
important to monitor electrolytes in patients taking digoxin since digoxin toxicity is potentiated by hypokalemia, hypomagnesemia, or hypercalcemia. Symptoms of
digoxin toxicity include nausea and vomiting with possible anorexia, dizziness, weakness, mental disturbanc-

es (such as confusion or hallucinations) and blurred
or yellow vision. In addition, concomitant use of
digoxin with amiodarone, dronedarone, or verapamil can worsen symptoms of toxicity as these
medications can increase serum digoxin levels. The
mechanism of interaction is likely due to inhibition of P-glycoprotein (P-gp) resulting in increased
bioavailability of digoxin. Patients that present with
symptoms of toxicity should have their serum drug
concentration checked as this medication has a
narrow therapeutic window. The goal therapeutic
range of digoxin for the indication of Afib is 0.8 to
2.0 ng/mL.14 There is no added treatment benefit
with serum concentrations above 2.0 ng/mL; however, risk for toxicity increases substantially beyond
that point. Furthermore, it is possible for patients
to fall in the therapeutic range but still present with
symptoms of toxicity. Digoxin serum concentrations
should be drawn at least 6 hours after the last dose
if given IV or at least 8 hours after the last dose
if given orally. Levels should not be drawn within
2 hours of exercise because of increased skeletal
muscle uptake of digoxin. Digoxin accumulates in
acute kidney injury and chronic kidney disease so
it is justified to check serum drug concentration
after one week of therapy. Patients with recurrent
hospitalization for HF exacerbation, hypotension,
or who are sedentary/bed-bound have compelling
indications for treatment with digoxin.
Rhythm Control Recommendations
Rhythm control therapy can be considered in
patients who have symptomatic POAF but are hemodynamically stable. Restoration of normal sinus
rhythm (NSR) through pharmacologic cardioversion
will generally eliminate symptoms of POAF and
may lead to better overall patient satisfaction. This
method of POAF treatment may also be considered
in patients where rate control agents are ineffective
or intolerable. This section reviews antiarrhythmic
agents, their mechanisms of action, potential ADRs,
dosing recommendations, and contraindications/
limitations. Specific agent choice depends on
several factors, including presence of underlying
structural heart disease, renal function, potential
toxicities, and provider experience. These medications require careful monitoring to minimize ADRs
and toxicities, which can lead to additional arrhythmias, extracardiac toxicities, and increased length
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of hospital stay. Important monitoring parameters for
these medications include EKG telemetry monitoring
with QTc interval measurement, vital signs including
blood pressure and heart rate, electrolytes, and other labs such as serum creatinine (SCr) and complete
blood count (CBC). Additionally, signs and symptoms
of toxicities should be assessed frequently. A summary of these medications can be found in Table 3.
Amiodarone (Nexterone - IV, Pacerone - Oral):
Amiodarone prolongs the action potential by inhibiting the inward potassium current and is therefore a
Vaughan Williams class III agent. It is also a noncompetitive α- and β-adrenergic inhibitor. Amiodarone
can be used for cardioversion from Afib to sinus
rhythm or for maintenance of sinus rhythm. Cardioversion dosing consists of 150 mg IV over 10 minutes,
then 1 mg/minute for 6 hours, then 0.5 mg/minute
for 18 hours or change to oral maintenance dosing
of 100-400 mg daily.15 The 2014 AATS Guidelines for
POAF recommend prophylactic amiodarone dosing
of 300 mg IV bolus, then 600 mg orally twice daily for
3-5 days. The IV bolus and first oral dose of 600 mg
are to be given together immediately after surgery. A
variety of regimens for preventing POAF have been
used in clinical trials but the AATS guideline recommendation is based on the dosing regimen utilized
in a randomized, double-blinded, placebo controlled
trial in patients undergoing surgery for lung cancer.16 Amiodarone has an unpredictable time course
of effect so loading doses should only be administered in a hospital setting. Acute adverse effects of
amiodarone include bradycardia, QT interval prolongation, arrhythmias, and hypotension. Heart rate and
blood pressure should be monitored regularly. Baseline QT interval should be measured with additional
follow up measurements throughout the course of
treatment along with electrolytes. More serious
adverse effects are seen in long-term amiodarone
use like pulmonary toxicity, hepatic disorders, hyper
or hypothyroidism, neurologic disorders including
fatigue and peripheral neuropathy, blue skin discoloration, and visual disturbances. Additional monitoring
includes baseline chest x-ray, pulmonary function
tests, liver function test, and thyroid function. These
should also be monitored periodically during therapy
along with routine eye exams. Amiodarone should
be used cautiously in patients on oral anticoagulation
as it inhibits the metabolism of warfarin and inhibits

the elimination of the new oral anticoagulants. There
is no well-established relationship between plasma
concentration and effectiveness so serum drug concentration monitoring is not warranted.
Flecainide (Tambocor):
Flecainide is a Vaughan Williams class IC antiarrythmic agent. It slows conduction in cardiac tissue
by altering transport of ions across cell membranes.
Flecainide is only manufactured as an oral dosage
form in the United States. Dosing for conversion to
sinus rhythm is 200-300 mg as a single oral dose
and sinus rhythm is maintained by 50-150 mg orally
every 12 hours.17 Adverse effects include dizziness
and visual abnormalities such as blurred vision and
difficulty focusing. Flecainide is less tolerated in patients with structural heart disease as these patients
may experience ventricular proarrhythmias. Flecainide is contraindicated in patients with heart failure
with reduced ejection fraction (HFrEF), due to potent
negative inotropic activity, and in coronary artery
disease (CAD)/structural heart disease. Additionally,
class IC antiarrythymic medications are listed in the
Beers Criteria so they are not first-line treatment for
Afib in the geriatric population.18 Select patients are
eligible for the “pill-in-the-pocket” administration approach for cardioversion. Eligible candidates for this
approach have infrequent paroxysmal atrial fibrillation with no other cardiac symptoms and have no
structural heart disease. These patients take either
flecainide or propafenone on an as-needed instead
of scheduled basis. This therapy demonstrated a
significant reduction in emergency room visits and
hospitalizations in a clinical trial.19
Dofetilide (Tikosyn):
Dofetilide is a Vaughan Williams class III antiarrythmic agent. The mechanism of action is to create
a prolonged action potential as a result of delayed
repolarization by blocking IKr channels. Dofetilide
may not be an ideal choice for cardioversion to sinus
rhythm in the postoperative setting as it may take
2-3 days to cardiovert and would therefore require
anticoagulation therapy for stroke prevention. Maintenance dosing for dofetilide depends on renal function as follows: 0.5 mg orally every 12 hours for CrCl
>60 mL/min, 0.25 mg orally every 12 hours for CrCl
40-60 mL/min, and 0.125 mg for CrCl 20-40 mL/min.
Dofetilide is contraindicated in patients with CrCl <20
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mL/min and for QTc interval >470 msec in men or
>480 msec in women.20 Other side effects include QT
prolongation and torsades de pointes (TdP), especially in patients with heart failure. Dofetilide carries a
unique treatment initiation limitation as it must be
started in the inpatient setting to complete 2 hours of
EKG monitoring after each dose for at least 3 days of
therapy.
Dronedarone (Multaq):
Dronedarone is a Vaughan Williams class III antiarrhythmic and has a similar mechanism of action
to amiodarone which inhibits multiple ion currents
including sodium, potassium, and calcium currents.
Additionally, dronedarone is a noncompetitive β-adrenergic inhibitor. Dronedarone was associated with
an increased incidence of mortality compared to
amiodarone and is therefore contraindicated in patients with NYHA class III to IV heart failure, unstable
NYHA class II heart failure, and in patients with permanent Afib.21 Furthermore, efficacy of dronedarone
for maintenance of normal sinus rhythm has only
been shown in patients with nonsurgical paroxysmal
Afib and therefore does not qualify as a potential
treatment for POAF.
Ibutilide (Corvert):
Ibutilide is a Vaughan Williams class III antiarrhythmic agent. It delays repolarization by activation
of slow, inward sodium current and IKR. Ibutilide is
only available as an IV dosage form and is therefore
only used for cardioversion to NSR and not for maintenance of NSR. This medication is dosed based on
weight as follows: 1 mg IV over 10 min for weight
≥60 kg or 0.01 mg/kg IV administered over 10 min for
weight <60 kg.22 Side effects that limit the use of ibutilide include QT interval prolongation and TdP. The
risk for TdP is 2 to 3 fold higher in patients with systolic heart failure. A small prospective randomized pilot
study compared ibutilide to propafenone and a rate
control arm. The study found that while every patient
given ibutilide was successfully cardioverted, 90% of
these patients also experienced recurrent Afib.23 This
was statistically significant compared to the lower
rate of recurrence for both propafenone and the rate
control arm. Ibutilide may be considered for patients
with structural heart disease and new-onset POAF
without hypotension or CHF. Patients must be monitored for at least 6 hours after receiving ibutilide.

Procainamide (Procainamide HCl):
Procainamide is a Vaughan Williams class 1A
antiarrhythmic agent. It blocks fast sodium channels
which increases the effective refractory period of the
atria, and to a lesser extent the ventricles. It is only
available as an IV formulation and is therefore only
indicated for the conversion of Afib to sinus rhythm
but not for maintenance of sinus rhythm. Additionally, procainamide has only been shown effective for
conversion in nonoperative Afib as conversion after
noncardiac thoracic surgery has not been investigated. Dosing of procainamide is more difficult and
requires close monitoring to assess appropriate
dose. It is dosed at 20-50 mg/min IV continuous infusion until Afib terminated, hypotension occurs, QRS
duration prolonged by 50%, or cumulative total dose
of 15 mg/kg reached. Alternative dosing includes 100
mg IV every 5 minutes until Afib terminated or previous mentioned conditions are met.24 Procainamide is
contraindicated in patients with systolic heart failure
or pretreatment QTc interval >470 ms in men or >480
ms in women.
Propafenone (Rythmol):
Propafenone is a Vaughan Williams class 1C
antiarrhythmic agent. It reduces upstroke velocity of
the action potential which is phase 0. A single oral
dose of 450-600 mg is effective for conversion of
nonsurgical Afib to sinus rhythm. Propafenone is also
effective for maintenance of sinus rhythm in patients
with nonoperative Afib at doses of 150-300 mg (immediate release) orally every 8 hours or 225-425 mg
(extended release) orally every 12 hours.25 There are
only oral formulations of propafenone. Side effects
include dizziness, blurred vision, sinus bradycardia,
and AV block. Propafenone is contraindicated in
patients with systolic heart failure or CAD/structural
heart disease.
Sotalol (Betapace AF):
Sotalol has both Vaughan Williams class II and
class III antiarrhythmic properties since it is a racemic
mixture. Sotalol is noncardioselective as it blocks β-1
and -2 receptors leading to decreased heart rate and
AV nodal conduction. Sotalol also prolongs atrial and
ventricular action potentials by inhibition of the IKr
channels that satisfy class III properties. The class III
effects are only seen at oral doses ≥160mg/day. Sotalol is only formulated as an oral dosage form with a
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maintenance dose of 40-160 mg orally every 12 hours
with the interval requiring adjustment based on kidney function. For CrCl 30-59 mL/min, administer dose
every 24 hours. Administer dose every 36-48 hours in
patients with CrCl of 10-29 mL/min.26 Side effects of
sotalol include sinus bradycardia, AV block, QT interval
prolongation, TdP, heart failure, and bronchospasm.
Sotalol has been used to reduce the risk of Afib after
CABG surgery but is not used for conversion of Afib to
sinus rhythm. Sotalol is contraindicated in patients with
pretreatment QTc interval >470 ms in men or >480 ms
in women.
Quinidine (Quinidine gluconate - IV):
Quinidine is a Vaughan Williams Class 1A antiarrhythmic agent. It inhibits both sodium and potassium
channels. Quinidine can induce QT interval prolongation that leads to TdP and may increase mortality.
Therefore, quinidine has fallen out of favor for use in
management of Afib as there are safer and more efficacious agents available.
Management of Patients with Preexisting Afib
Elderly patients, who commonly have multiple
comorbidities due to their advanced age, are a large
portion of patients requiring cardiothoracic surgery.
Oftentimes this patient population will present with
preexisting Afib preoperatively. The 2014 AATS POAF
guidelines recommend that cardiology consultations
be obtained for these patients, and that they should be
treated according to the existing guidelines for nonsurgical Afib, namely the recently released 2014 AHA/
ACC/HRS guidelines for Afib management.15
AATS recommends that for patients with preexisting Afib, decisions regarding interruption of
anticoagulation for surgery be made based on the
patient’s stroke risk versus bleed risk.1 This is done
with the guidance of the CHA2DS2-VASc score (Figure
1). In patients with a high risk for stroke (equating to a
CHA2DS2-VASc score of ≥2), history of a prior stroke,
or mechanical heart valve, perioperative bridging with
a parenteral anticoagulant (i.e. enoxaparin) is reasonable. For patients with a lower risk, short-term withdrawal without bridging may be appropriate.
Conclusion
Postoperative atrial fibrillation is a major complication of thoracic surgery that, with evidence-based practice, is often preventable. This complication has several
implications, the most worrisome being thromboem-

boli formation resulting in stroke. The guidelines
presented here have provided the most up-to-date
recommendations on prophylaxis for POAF, treatments strategies, and anticoagulation in patients
presenting with chronic Afib. It is important that
pharmacists understand the current treatment
guidelines for critical care patients such as those
undergoing cardiothoracic surgery. Ensuring the
proper pharmacological therapy in these patients
will help establish better treatment outcomes, decrease hospital length of stay, and save money and
resources.
Table 1. Modifiable and nonmodifiable risk factors for
postoperative atrial fibrillation.1
Modifiable
Hypertension
Myocardial Infarction
Valvular Heart Disease
Heart Failure
Obesity
Obstructive Sleep Apnea
Smoking
Exercise
Alcohol use
Hyperthyroidism
Increased Pulse Pressure

Nonmodifiable
Increasing age
African American (protective)
Family History
Genetic Variance
Male Sex
History of Arrhythmias

Mitral Regurgitation
Left Ventricular Hypertrophy

Figure 1. CHA2DS2-VASc scoring system for the prediction of stroke risk in patients with atrial
fibrillation. A maximum score of 9 is possible. Scores of ≥2 are considered high risk. Adapted from the
2014 AATS POAF guidelines.1

LV=left ventricular, BP=blood pressure, HTN=hypertension, TIA=transient ischemic attack, MI=myocardial infarction, PVD=peripheral vascular
disease

Condition

Points

C

Congestive heart failure (or LV dysfunction)

1

H

Hypertension BP>140/90 (or treated HTN)

1

A

Age ≥75 years

2

D

Diabetes Mellitus

1

S

Prior stroke or TIA or Thromboembolism

2

V

Vascular disease (MI, PVD, Aortic plaque)

1

A

Age 65-74 years

1

Sc

Sex Category (female)

1

2

2

Figure 2. Vaughan Williams classification of agents. 27

Vaughn-williams Classification
Class I Sodium-channel-blocking drugs:

Class IA - Moderately slow conduction, moderately prolonged action potential duration:
Quinidine
Procainamide
Disopyramide
Class IB - Minimally slow conduction, shortened action potential duration:
Tocainide
Lidocaine
Mexiletine
Phenytoin
Class IC - Markedly slow conduction, minimally prolonged action potential duration:
Flecainide
Encainide
Propafenone
Moricizine
Class II Beta-blocking drugs
Class III Potassium-channel-blocking drugs - prolonged action potential duration:
Amiodarone
Bretylium
Sotalol
Ibutilide
Class IV Calcium-channel-blocking drugs

Perioperative
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Table 2. Rate control agents and their clinical pearls.1
Name

Renal
Adjust*

Monitoring

ADEs

Clinical Pearls

Esmolol
(Brevibloc)

No

HR, BP, telemetry/EKG

Hypotension, bradycardia, AV
block, fatigue, dizziness

Titrate dose to goal HR

Metoprolol
(Lopressor)

No

HR, BP, telemetry/EKG

Hypotension, bradycardia, AV
block, fatigue, dizziness

Oral dosage form available for
long-term maintenance

Diltiazem
(Cardizem)

No

HR, BP, telemetry/EKG

Hypotension, bradycardia, AV
block, worsening of HF, peripheral
edema, constipation

Titrate dose to goal HR

Digoxin
(Lanoxin)

Yes

K+, Mg2+, serum drug
level, HR,
telemetry/EKG

N/V, anorexia, confusion, visual
disturbances, AV block, ventricular
arrhythmias

Therapeutic serum concentration:
0.8-2ng/mL, does not appreciably
effect BP, synergistic with βB/CCB

HR= heart rate, BP= blood pressure, EKG=electrocardiogram, AV=atrioventricular, HF=heart failure, K+=potassium, Mg2+=magnesium,
N/V=nausea/vomiting, βB=beta-blocker, CCB=calcium channel blocker,

Table 3. Rhythm control agents and their clinical pearls.1
Name

Renal
Adjust*

Monitoring

ADEs

Clinical Pearls

Amiodarone
(Nexterone)

No

HR, BP, QTc interval,
telemetry/EKG

Bradycardia, hypotension, QTc
prolongation, AV block

DDI with warfarin

Flecainide
(Tambocor)

Yes

HR, BP, telemetry/EKG

Dizziness, blurred vision,
bradycardia, AV block

CI in HFrEF and
CAD/structural heart disease

Dofetilide
(Tikosyn)

Yes

HR, BP, QTc interval,
telemetry/EKG

QTc prolongation, TdP

Must be started as an
inpatient

Dronedarone
(Multaq)

No

HR, BP, telemetry/EKG

GI upset, dizziness,
bradycardia

CI in HF and permanent Afib

Ibutilide
(Corvert)

No

HR, BP, QTc interval,
telemetry/EKG

QTc prolongation, TdP

Not indicated for
maintenance of SR

Procainamide

Yes

HR, BP, QTc interval,
telemetry/EKG

Hypotension, QTc
prolongation, TdP

CI in HFrEF, Not indicated
for maintenance of SR

Propafenone
(Rhythmol)

No

HR, BP, telemetry/EKG

Dizziness, blurred vision,
bradycardia, AV block

CI in HFrEF and
CAD/structural heart disease

Sotalol
(Betapace AF)

Yes

HR, BP, QTc interval,
telemetry/EKG

Bradycardia, AV block, QTc
prolongation, worsening HF

May be used with a “pure
beta blocker”

HR= heart rate, BP= blood pressure, QTc=corrected QT interval, EKG=electrocardiogram, AV=atrioventricular, DDI=drug-drug interaction,
CI=contraindicated, HFrEF=heart failure with reduced ejection fraction, CAD=coronary artery disease, GI=gastrointestinal, TdP=torsades de
point, SR=sinus rhythm, HF=heart failure
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I.

CONTINUING EDUCATION QUIZ QUESTIONS

Comparing the 2013 ACC/AHA & 2014 NLA Dyslipidemia Guidelines and their Impact on
Clinical Decision Making
ACPE UAN# 0100-0000-15-043-H04-P; 0100-0000-15-043-H04-T
1. The ACC/AHA recommends utilizing
which risk assessment calculator?
a. Pooled Cohort equations
b. Framingham risk calculator
c. Framingham long-term risk calculator
d. A & B
e. All of the above
2. AD is a 56 year-old male who presents to
the lipid clinic for evaluation of his cholesterol. He has never had a fasting lipid panel
performed and was referred to the clinic
by his primary care physician. According
to the NLA, which component of a fasting
lipid panel is considered a primary target
for modification?
a. LDL-C
b. Non-HDL-C
c. apoB
d. HDL-C
3. AD’s fasting lipid panel results reveal an
LDL-C of 196mg/dL. How would you classify AD’s risk based on his LDL-C level alone,
based on the NLA recommendations?
a. Low risk
b. Moderate risk
c. High risk
d. Very high risk
4. Based on AD’s above risk category, what
pharmacotherapy would you recommend
initiating, per the NLA recommendations?
a. Atorvastatin 40mg daily
b. Pravastatin 20mg daily
c. Lovastatin 40mg daily
d. Simvastatin 20mg daily
5. Which of the following is/are considered
clinical ASCVD?
a. Myocardial infarction
b. Stroke/TIA
c. Peripheral artery disease
d. All of the above
6. Which of the following medications
should be selected for a patient with Type
II diabetes and a non-HDL-C of 128 mg/dL
according to the NLA recommendations?
a. Fenofibrate 145 mg daily
b. Niacin 100 mg TID
c. Atorvastatin 20 mg daily Ezetimibe 10 mg
daily
7. MJ is a 44 year-old male who has been
referred to your facility’s lipid clinic for
the management of his dyslipidemia. He
has a LDL-C of 164 mg/dL and a HDL-C of
58 mg/dL. The patient reports that his
father passed away at 54 years of age from
a heart attack, but his mother is healthy
without any significant health concerns. He

has hypertension with a blood pressure
reading of 158/92 mm Hg today at his
follow-up visit. How many risk factors for
ASCVD does this patient have?
a. 0
b. 1
c. 2
d. 3
8. Which of the following statements is
true about non-HDL-C and Apo B?
a. Both are considered a secondary target
in the treatment of atherogenic cholesterol in the NLA recommendations for the
treatment of dyslipidemia.
b. Neither of the two requires fasting
prior to a lipid panel for accurate assessment.
c. Apo B has shown superiority to nonHDL-C in randomized controlled trials in
predicting ASCVD risk.
d. The treatment goals for non-HDL-C and
Apo B are the same despite which risk
category the patient falls under.
9. You are a pharmacist on rounds with
a physician in the hospital setting. Your
primary responsibility this morning as
the pharmacist is to provide recommendations for the renal dose adjustment
of medications in a patient with stage 4
chronic kidney disease. The patient is 65
years old, smokes one pack of cigarettes
per day and has stage II hypertension.
The results of the lipid panel confirm
that the patient has dyslipidemia with a
non-HDL-C of 155 mg/dL and an LDL-C of
110 mg/dL. The physician wants to start
a statin in this patient but is unfamiliar
with the new NLA recommendations
and what risk category the patient falls
under. He also wants to know what the
patient’s goal non-HDL-C is based on
his risk category. What is the correct
response to the physician?
a. The patient is at moderate risk with a
non-HDL-C goal of <130 mg/dL
b. The patient is at very high risk with a
non-HDL-C goal of <100mg/dL
c. The patient is at high risk with a nonHDL-C goal of <130 mg/dL
d. You cannot give an appropriate answer
at this time because quantitative risk
scoring is required to further assess the
patient’s risk category and cholesterol
goals.
10. Comparing the 2013 ACC/AHA guidelines and the 2014 NLA recommendations what is/are the major differences?

a. The NLA recommendations use of
non-HDL-C, LDL-C, and Apo-B target goals
in the treatment of dyslipidemia where
the ACC/AHA guidelines do not utilize
treatment goals.
b. The NLA recommendation of using
Apo-B as the primary lipid measure to target treatment goals as opposed to LDL-C
by the ACC/AHA guidelines.
c. The NLA recommendation of using
fibrates as an initial treatment option in
patients that fall into the moderate risk
ASCVD group compared to the ACC/AHA
guidelines that recommend statin use
first line.
d. A and C
11. Which of the following statements of
the NLA recommendations is true:
a. Patients that fall into the very high risk
ASCVD category should have an initial TLC
trial prior to pharmacotherapy initiation.
b. The NLA does not recommend the use
of quantitative risk scoring in patients
being evaluated for dyslipidemia that fall
into the high and very high risk categories
as it typically underestimates their risk for
an ASCVD event.
c. TLC changes such as initiating or increasing exercise regimens to 30 minutes/
day, adding 5-10g of viscous fiber to diet,
and 5-10% weight loss for all patients
should be started at initial evaluation for
patients who have dyslipidemia.
d. The NLA recommends fibrates, nicotinic acids, and statins to be considered first
line therapy in treating patients newly
diagnosed with dyslipidemia.
Use the following patient case to #12-14:
RD is a 63 years old male (70in, 249lbs)
with a history of COPD, DM, 1 PPD smoker, total hip replacement and HTN. He
is returning after 3 months to the clinic
where you the clinical pharmacist have
authority to adjust pharmacotherapy in
patients with dyslipidemia. RD is complaining of muscle pain and weakness at
his follow up visit after he was started on
atorvastatin 40mg.
Creatinine Kinase: within normal limits
LFTs: within normal limits Non-HDL cholesterol(baseline/current): 232/156 mg/
dL; HDL-C(baseline/current): 40/45 mg/dL
TG (baseline/current): 430/389mg/dL;
Current BP is 132/78; Current meds: Lisinopril 40mg PO daily, amlodipine 10mg
PO daily, Metformin 1000mg PO BID,
Glipizide 5mg PO BID, Symbicort 160/4.5

2 puffs BID
12. Based on RDs current status the most appropriate
change to therapy would be to:
a. Discontinue atorvastatin 40mg as it causing myopathies.
b. Decrease his dose of atorvastatin to 20mg and add long
chain omega-3 fatty acids to decrease his TG.
c. Change atorvastatin to rosuvastatin 20mg.
d. Stop all statin use as RD is intolerant to statins and start
fenofibrate 135 mg.
13. What therapeutic lifestyle changes (TLC) should be recommended to RD to help him reach his non-HDL-C goal:
a. Counsel RD on smoking cessation and refer him to the
Arizona Smokers Helpline (ASH-Line)
b. Suggest moderate exercise for 30 minutes per day, 7 days

II.

week, as possible
c. Recommend following DASH diet
d. All of the above are appropriate lifestyle changes
14. RD returns to the clinic after another 3 months after following the recommendations made at his previous visit. His current
non-HDL-C is 130mg/dL. Which of the following is false?
a. RDs adherence and tolerability to his pharmacotherapy and TLC
need to be assessed.
b. RD has reached his non-HDL-C goal and can discontinue therapy
and follow up in 12 months.
c. RD should be evaluated and encouraged for smoking cessation.
d. TLC changes should be discontinued as he has reached his goal
non-HDL-C.
e. B and D

A Pharmacist’s Role in the Prevention and Management of Perioperative Atrial Fibrillation and Flutter
ACPE UAN# 0100-0000-15-044-H03-P; 0100-0000-15-044-H03-T

1. Which of the following is a major complication associated with POAF?
a. Vision changes
b. Insufficient blood flow leading to poor perfusion to the body
c. Moderate to severe skin reactions
d. Increased risk of bleed due to inability to
coagulate
2. Which is/are symptoms of POAF?
a. Excessive weight gain
b. Increased thirst (polydipsia) and increased
urination (polyuria)
c. Brittle nails
d. Hypotension and fatigue
3. Which of the following statements is TRUE
regarding β-blockers?
a. β-blockers are Vaughan Williams class IV
agents
b. Tachycardia and hypertension are common
side effects of β-blocker therapy
c. IV dosing of metoprolol tartrate (Lopressor) is
12.5-25 mg IV bolus over 2 min for a maximum
of three doses
d. Patients with systolic heart failure and/or
CAD have a compelling indication for β-blocker
therapy
4. JW is a 72 yo M who is currently taking metoprolol tartrate 50 mg BID. He has no history
of AF but is undergoing a pulmonary segmentectomy. Which of the following statements is
most accurate?
a. JW should be started on digoxin 0.125 mg for
AF prophylaxis
b. Metoprolol should be discontinued prior to
surgery
c. Continue metoprolol since JW was taking
prior to surgery
d. Beta-blocker therapy is contraindicated in
thoracic surgeries

5. Which of the following is a unique side
effect of diltiazem?
a. Constipation
b. Diarrhea
c. Visual disturbances
d. Alopecia
6. All of the following are monitoring
parameters for digoxin EXCEPT:
a. Serum drug concentration (goal: 0.8 2.0 ng/mL for Afib)
b. Electrolytes
c. Liver function
d. Kidney function
7. Which of the following statements
regarding amiodarone is FALSE?
a. Amiodarone can be used for cardioversion from AFib to sinus rhythm or for
maintenance of sinus rhythm.
b. Amiodarone is available in IV and oral
formulations.
c. Amiodarone does not cause bradycardia or hypotension.
d. Amiodarone should be used cautiously
in patients on oral anticoagulation as it
inhibits the metabolism of warfarin and
inhibits the elimination of the new oral
anticoagulants.
8. Which rhythm control agent must
be started in an inpatient setting for a
minimum of 3 days?
a. Propafenone
b. Amiodarone
c. Dofetilide
d. Verapamil
LT is a 68 y/o female s/p thoracic surgery.
Her BP is 132/88 with a HR of 78. She
is hemodynamically stable yet having
symptoms of AFib including shortness
of breath, fatigue, and confusion. Rate

control agents are not sufficiently treating
POAF in LT. Use this case for #9 – 10.
9. LT is a candidate for rhythm control for
POAF.
a. True
b. False
10. Which of the following medications
cannot be used to cardiovert LT?
a. Amiodarone
b. Sotalol
c. Ibutilide
d. All of these can be used to pharmacologically cardiovert.
11. Which of the following is NOT a recommendation provided by the 2014 AATS
guidelines for preventing POAF?
a. Supplemental intravenous magnesium
should be considered for patients in which
serum magnesium levels are low
b. Patients taking beta-blockers prior to
surgery to continue to take them in the
postoperative period
c. Initiate sotalol preoperatively as prophylaxis for POAF
d. Digoxin should not be used for preventing POAF
GL is a 72 y/o male who will be undergoing
a lung transplantation next week. His PMH
includes chronic Afib, DM, HTN and gout.
12. GL’s CHA2DS2-VASc score is:
a. 1
b. 2
c. 3
d. 4
13. Perioperative anticoagulation bridging
should be considered for GL:
a. True
b. False
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